A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B

PharmacoEconomics

Volumn 26, Issue 11, 2008, Pages 937-949

  Spackman, D Eldon ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adefovir, therapeutic use; Cost utility; Entecavir, therapeutic use; Hepatitis B, treatment; Lamivudine, therapeutic use; Peginterferon alfa 2a, therapeutic use; Research and development; Telbivudine, therapeutic use

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE;

ARTICLE; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MARKOV CHAINS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 53849086193     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826110-00006     Document Type: Article

References (54)

1. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158-68
2. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003; 362: 2089-94
3. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006; 13: 787-98
4. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62
5. Lee TA, Veenstra DL, Iloeje UH, et al. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004; 38: S144-7
6. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29
7. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352: 2743-6
8. Lok A, McMahon B. AASLD practice guidelines: chronic hepatitis B. Hepatology 2007; 45: 507-39
9. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25: 963-77
10. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214-46
11. Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870-6
12. Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21: 531-7
13. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9
14. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13
15. Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: iii-iv, xi-xiv, 1-183
16. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006; 295: 65-73
17. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol ogy 2006; 130: 678-86
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51
19. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10
20. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16
21. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88
22. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95
23. Marcellin P, Chang TT, Lim SG, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. American Association for the Study of Liver Diseases; 2004 29 Oct-2 Nov; Boston (MA)
24. Qi X, Snow A, Thibault V, et al. Long-term incidence of adefovir dipivoxil resistance in chronic hepatitis B patients after 144 weeks of therapy. European Association for the Study of the Liver (EASL); 2004 Apr 14-18; Berlin
25. Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. 18th Conference of the Asia-Pacific Association for the Study of the Liver (APASL); 2008 Mar 23-26; Seoul
26. Han SH, Lai CL, Gane E, et al. Telbivudine GLOBE trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B. In Digestive Disease Week; 2007 May 24-27; Washington DC
27. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90
28. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37
29. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic, and biochemical response over time [abstract no. 1135]. Hepatology 2004; 40: 655A
30. Heathcote E, Jeffers L, Perrillo R, et al. Sustained anti-viral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection [abstract no. 590]. 37th Annual Meeting of the European Association for the Study of the Liver; 2002 Apr 18-22; Madrid
31. Hepsera® (adefovir dipivoxil tables) [package insert]. Foster City (CA): Gilead Sciences, Inc., 2006
32. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5
33. Veenstra DL, Sullivan SD, Dusheiko GM, et al. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Eur J Gastroenterol Hepatol 2007; 19: 631-8
34. AnalySource. Wholesale acquisition cost. New York: AnalySource Inc., 2008
35. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 153-64
36. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821-31
37. Levy AR, Gagnon YM, Hargreaves SJ, et al. Valuing health states using utility weights to capture the impact of disease progression in chronic hepatitis B. World Congress of Gastroenterology; 2005 Sep 9-14; Montreal (QC)
38. Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75
39. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005; 8: 1-2
40. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-87
41. Fenwick E, Marshall DA, Levy Ar, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006; 6: 52 [online]. Available from URL: http://www.biomedcentral.com/1472-6963/6/52 [Accessed 2008 Sep 12]
42. Groot Koerkamp B, Hunink MG, Stijnen T, et al. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making 2007; 27: 101-11
43. Wilber R, Brett-Smith H, Zhu J, et al. Entecvir (ETV) vs adefovir (ADV): HBV DNA reduction in chronically infected HBeAg (+) nucleoside-naive adults in a 12-week viral kinetics study. NIH Management of Hepatitis B Conference; 2006 Apr 6; Bethesda (MD)
44. Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008; 14: 21-33
45. Smith VE, Bruno CJ. The search for cost-effective treatment of chronic hepatitis B. J Manag Care Pharm 2008; 14: 61-4
46. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101: 2076-89
47. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-54
48. Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-8
49. Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol 2008; 48: 383-6
50. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 Jul 9; 339 (2): 61-8
51. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996 May 30; 334 (22): 1422-7
52. Crowley SJ, Tognarini D, Desmond PV, et al. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 409-27
53. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
54. Degertekin B, Lok AS. When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med 2007; 147: 62-4